Liraglutide, a long‐acting GLP‐1 analog with 97% structural homology to the native hormone [2], binds to the GLP‐1 receptor, displaying a similarly broad range of activities relevant to improving glycemic control for treating type 2 diabetes. The gene discussed is GCG; the disease is type 2 diabetes mellitus.